77
Participants
Start Date
August 12, 2013
Primary Completion Date
November 16, 2020
Study Completion Date
May 31, 2028
brentuximab vedotin
Given intravenously (IV).
etoposide
Given IV.
prednisone
Given orally (PO).
doxorubicin
Given IV.
cyclophosphamide
Given IV.
Dacarbazine(R)
Given IV.
filgrastim
Given subcutaneously (SQ) as clinically indicated.
quality of life assessment
Quality of life assessment will be done at initial clinical visit, and during chemotherapy, completion of therapy, then at 1 year, 2 years and 5 years. It should take no more than 15-20 minutes to complete. Participation is voluntary by participating institution and by participant.
radiation therapy
At the end of chemotherapy and recovery of blood counts, radiotherapy will be given to any involved nodes (if any) that are not in complete remission.
St. Jude Children's Research Hospital, Memphis
St. Jude Midwest Affiliate, Peoria
Lucile Packard Children's Hospital Stanford University, Palo Alto
Maine Children's Cancer Program (MCCP), Scarborough
Massachusetts General Hospital Cancer Center, Boston
Dana-Farber Harvard Cancer Center, Boston
Seagen Inc.
INDUSTRY
St. Jude Children's Research Hospital
OTHER